Skip to content

Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area

Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00139100
Enrollment
200
Registered
2005-08-31
Start date
2001-02-28
Completion date
2002-03-31
Last updated
2008-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cellulitis, Lymphedema

Brief summary

Introduction. Lymphatic filariasis is a devastating mosquito-transmitted parasitic disease that causes lymphedema or elephantiasis of the leg in 15 million persons, the majority of whom are women. In these persons, frequent bacterial infections (acute attacks) of the legs adversely affect physical health, economic well-being, and quality of life. Prevention of bacterial infections through hygiene and skin care can result in significant improvements in lymphedema and patient well-being. Methods. To determine the extent to which antibacterial soap can help reduce the incidence of acute bacterial infections of the lower limbs in persons with filarial lymphedema, 200 patients of the Ste. Croix Hospital lymphedema treatment clinic in Leogane, Haiti randomly assigned to receive either antibacterial (Safeguard) or placebo (Camay) soap and acute attacks monitored monthly for 12 months. Both groups received specific instructions on washing and skin care.

Interventions

DRUGantimicrobial agent in soap

Sponsors

Procter and Gamble
CollaboratorINDUSTRY
Ste. Croix Hospital, Leogane, Haiti
CollaboratorUNKNOWN
Centers for Disease Control and Prevention
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

Patients eligible for participation include those who are currently enrolled in the lymphedema treatment program in Leogane who 1) have been trained in the techniques of self-care, 2) who live in a 10-km radius of the hospital, and 3) for whom we have adequate data on incidence of acute bacterial infections, risk factors for infection, and ability to comply with the treatment protocol (particularly hygiene). \-

Exclusion criteria

Don't meet inclusion criteria. \-

Design outcomes

Primary

MeasureTime frame
Incidence of bacterial acute attacks, assessed monthly.
Reported or observed severity of these acute attacks.
Duration of acute attacks.

Secondary

MeasureTime frame
Demonstrated knowledge and ability to wash leg appropriately during home visits.
Reported patient satisfaction with soap.
Process measures
Number of bars of soap used per patient per month.
Reported frequency of leg washing.

Countries

Haiti

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026